ArticleHLA2019
TypeLoader2: Automated submission of novel HLA and killer-cell immunoglobulin-like receptor alleles in full length.
Article in HLA, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Advances inFrontiers in immunology · 2026Article
- Article
- Full-Length Characterization of Novel HLA-DRB1 Alleles for Reference Database Submission.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Submitting Novel Full-Length HLA, MIC, and KIR Alleles with TypeLoader2.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Article
- Immunogenetics in stem cell donor registry work: The DKMS example (Part 2).International journal of immunogenetics · 2020Review
- Bioinformatics Strategies, Challenges, and Opportunities for Next Generation Sequencing-Based HLA Genotyping.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2019Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Immuno Polymorphism Database (IPD) databases provide global, curated repositories for information regarding polymorphisms of genes of the immune system, thereby generating immense value for the research and clinical communities. The advent of high-throughput genotyping in immunogenetics has led to dramatically growing numbers of heretofore unknown HLA and lately also killer-cell immunoglobulin-like receptor (KIR) alleles, which are to be curated and deposited in the IPD-IMGT/HLA and IPD-KIR databases, respectively. It is highly desirable that these novel alleles are characterised and submitted in full length, and that known alleles are extended to cover the complete gene sequence. However, the manual annotation and submission of sequences to European Molecular Biology Laboratory's European Nucleotide Archive and the IPD-IMGT/HLA and IPD-KIR databases is time-consuming and error-prone. Here, we report the substantial extension of the HLA allele submission tool TypeLoader, which now also supports the annotation and submission of KIR alleles. To enable a more widespread use of this tool, we have made it available as a stand-alone application that can easily be installed on standard Windows or Linux computers. Furthermore, an internal SQLite database was added to store a wide range of metadata about each allele. This allows TypeLoader2 to be used as a lab's central information platform for the annotation, curation and submission of full-length HLA and KIR allele sequences. The software is freely available from GitHub (https://github.com/DKMS-LSL/typeloader). We hope that the increased convenience and scope of TypeLoader2 will foster the submission of more full-length sequences to the IPD-IMGT/HLA and IPD-KIR databases, ultimately promoting the use of full-length sequencing for genotyping both HLA and KIR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.